American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

A New Challenger for FCR in CLL: Ibrutinib + Rituximab

Dr. Becker compares ibrutinib-based therapy and FCR chemoimmunotherapy for CLL.

Read more

Navigating Future Challenges in Lymphoma: A Map for the Road Ahead

Drs. LaCasce and Weinstock discuss future challenges in lymphoma pathogenesis.

Read more

Antibody Therapy for the Treatment of Relapsed ALL

Dr. Raetz studies a different therapy for the treatment of relapsed ALL.

Read more
View All

Presidents Column

Dr_ David A_ Williams - Presidents Column

David A. Williams, MD

Chief of Hematology/Oncology; Director of Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts
Earnest Support for Careers and Cures
February 24, 2015

Dr. Williams shines a spotlight on the scholarships and awards ASH makes possible each year, and the successes of the numerous winners.

View All

Clinical Trials Corner

Antibody Therapy for the Treatment of Relapsed ALL
April 16, 2015

Dr. Raetz studies a different therapy for the treatment of relapsed ALL.

View All

Ask The Hematologist

Ask the Hematologist: Treatment with Direct Oral Anticoagulants
April 3, 2015

Dr. Garcia discusses treatment with direct oral anticoagulants (DOACs), after the FDA approval of edoxaban, the fourth DOAC to come to the U.S. market since 2010.

View All

Mini Review

Desialylated Platelets: A Missing Link in Hepatic Thrombopoietin Regulation
April 14, 2015

Drs. Falet, Grozovsky, and Hoffmeister look at desialylated platelets to understand the steady state of hepatic TPO regulation and the mechanisms of thrombocytopenia observed in patients with MPNs treated with JAK1/2 inhibitors.

View All

Op Ed

Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?”
November 19, 2014

Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.

View All
  • NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research

    The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise.  ASH members are encouraged to submit comments in response to this request.

  • CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy

    On March 30, the Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare Part B and Part D payment for biosimilars that are relevant to hematology.  On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic therapy.  Some of the most important regimens for the treatment of patients with hematologic disorders are biologic, so the release of this information is helpful for the field.

  • IOM National Cancer Policy Forum Releases a Report on Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

    The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies."  This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.

  • New SGR Bill Released

    On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue.  This bill largely follows the policy of the bill that was introduced by the committees of jurisdiction during the last Congress.  That bill, which ASH supported, eliminated the SGR update formula in favor of a new payment schedule.  Follow the link above to read more about the bill.

View all policy news
back to top